Next Article in Journal
Two Sides to One Story—Aroma Chemical and Sensory Signature of Lugana and Verdicchio Wines
Next Article in Special Issue
Allosteric Modulation of the CB1 Cannabinoid Receptor by Cannabidiol—A Molecular Modeling Study of the N-Terminal Domain and the Allosteric-Orthosteric Coupling
Previous Article in Journal
Glycan-Induced Protein Dynamics in Human Norovirus P Dimers Depend on Virus Strain and Deamidation Status
Previous Article in Special Issue
Traumatic Stress, Chronic Ethanol Exposure, or the Combination, Alter Cannabinoid System Components in Reward and Limbic Regions of the Mouse Brain
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 26
Issue 8
10.3390/molecules26082126
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB1/CB2 Receptor Interaction

by
Battistina Asproni
*,
Gabriele Murineddu
,
Paola Corona
and
Gérard A. Pinna
Department of Chemistry and Pharmacy, University of Sassari, Via Muroni 23/A, 07100 Sassari, Italy
*
Author to whom correspondence should be addressed.
Molecules 2021, 26(8), 2126; https://doi.org/10.3390/molecules26082126
Submission received: 3 March 2021 / Accepted: 29 March 2021 / Published: 7 April 2021
(This article belongs to the Special Issue Endocannabinoid System Modulators in a Medicinal Chemistry Perspective)
Browse Figures
Versions Notes

Abstract

:
Cannabinoids comprise different classes of compounds, which aroused interest in recent years because of their several pharmacological properties. Such properties include analgesic activity, bodyweight reduction, the antiemetic effect, the reduction of intraocular pressure and many others, which appear correlated to the affinity of cannabinoids towards CB1 and/or CB2 receptors. Within the search aiming to identify novel chemical scaffolds for cannabinoid receptor interaction, the CB1 antagonist/inverse agonist pyrazole-based derivative rimonabant has been modified, giving rise to several tricyclic pyrazole-based compounds, most of which endowed of high affinity and selectivity for CB1 or CB2 receptors. The aim of this review is to present the synthesis and summarize the SAR study of such tricyclic pyrazole-based compounds, evidencing, for some derivatives, their potential in the treatment of neuropathic pain, obesity or in the management of glaucoma.

1. Introduction

Cannabinoids are a class of different chemical compounds (Figure 1), including the endocannabinoids (produced naturally in the body by humans and animals such as anandamide and 2-arachidonoylglycerol), the phytocannabinoids (derived from Cannabis, exemplified by Δ9-tetrahydrocannabinol, the major psychoactive component of Cannabis sativa, commonly known as marijuana), and the synthetic cannabinoids (produced chemically by human, comprising a wide array of chemical entities, i.e., the pyrazole-based compounds SR141716A and SR144528 and the indole based compound WIN-55,212-2) [1,2,3]. The physiological and behavioral effects of cannabinoids appear directly correlated to their affinity towards two different classes of specific receptors: CB1 receptors located predominantly in the central nervous system [4], and CB2 receptors which are mostly found in peripheral tissues [5]. In the brain, the CB1 receptors are abundantly expressed in the hippocampus, cerebellum and striatum [6,7]. Among the peripheral tissues wherein the CB1 receptors have been found, the enteric nervous system [8], testis, urinary bladder, vas deferens can be mentioned [9]. CB1 receptor mRNA and protein have been furthermore identified in the rat and human eye, both in the retina and in the iris, and in the ciliary body [10]. CB2 receptors are located in the marginal zones of the spleen, tonsils, immune cells [9,11] and to a much lesser extent in CNS [12]. Furthermore, CB2 receptor mRNA was expressed in the adult rat retina, including the somas of retinal ganglion cells [13].
During the last years, several ligands endowed with high affinities and subtype selectivity for both receptors were identified. Such ligands were proposed as potential therapeutic targets for the treatment of several diseases, including neuropathic pain [14], cancer [15,16] and osteopor4osis [17].
Non-selective CB1/CB2 receptor agonists are the constituents of some approved medicines, i.e., Sativex®, Cesamet®, Marinol®. Sativex contains approximately equal amounts of Δ9-tetrahydrocannabinol and the non-psychoactive phytocannabinoid cannabidiol, and is prescribed for neuropathic pain relief in adults with multiple sclerosis and as an adjunctive analgesic treatment for adult patients in advanced cancer [18]. Furthermore, the relevance of CB receptors as an emerging target of pharmacotherapy is documented also by the discovery of mixed CB1/CB2 receptor agonists as antiglaucoma agents [19].
The only cannabinoid receptor antagonist approved as a medicine to-date is the CB1 antagonist/inverse agonist SR141716A (rimonabant, Acomplia®, Figure 1). This compound has been developed for the treatment of obesity and related metabolic risk factors [20]. However, it was soon withdrawn for its serious psychiatric disorders including anxiety, depression and suicidal tendency. Although most pharmaceutical companies were deterred from developing a drug that displayed rimonabant-like CB1 receptor antagonist/inverse agonist activity for the management of any disorders, this compound still remains an extremely valuable lead for the design of new ligands for CB receptors interaction [21,22]. Within this frame, the 4-alkyl-5-arylpyrazole skeleton of rimonabant has been modified, leading to benzocycloalkylpyrazole-based tricyclic systems of general formula I-IV (Figure 2). Modifications carried out on such scaffolds, allowed to accede to further pyrazole-based tricyclic systems of general formula V-XVII (Figure 2). Fine tuning of these tricyclic systems (vide infra) allowed to identify hundreds of molecules, most of which endowed with high affinity and selectivity for CB1 or CB2 receptors. In this review, pyrazole-based tricyclic compounds I-XVII are divided into four main groups according to the size of the central ring connected to the pyrazole one. If a five-membered ring is connected to the pyrazole, the compound belongs to (5,5)-condensed pyrazole derivatives, and if the connected ring is a six-, seven- or eight-membered ring, the compound belongs to (5,6)-, (5,7)- or (5,8)-condensed pyrazole derivatives. Here, we briefly present the synthesis and the bioactivities of pyrazole-based tricyclic compounds I-XVII investigated by us and other groups. Furthermore, this review surveys chemical and biological literature of some miscellaneous molecules featuring tricyclic pyrazole structure closely related to compounds I-XVII, investigated for cannabinoid receptor affinity.

2. (5,5)-Condensed Pyrazole Derivatives

2.1. 1,4-dihydroindeno(1,2-c)pyrazole-Based Derivatives

The first (5,5)-condensed pyrazole derivatives synthesized by us for cannabinoid receptors interaction are those of general formula I (Figure 2) featuring the 1,4-dihydroindeno(1,2-c)pyrazole core. These compounds were designed as rigid analogs of CB1 antagonist/inverse agonist SR141716A (rimonabant), endowed with a high affinity for CB1 receptors and good selectivity over CB2 receptors. It has been proposed that minimization of the flexibility of the lead compound through the introduction of structural constraints could have some impact on cannabinoid receptor interaction, maybe allowing the ligand to bind with high affinity and selectivity to its receptor. Accordingly, the first series of 1,4-dihydroindeno(1,2-c)pyrazole derivatives have been synthesized and evaluated for their in vitro binding affinities for CB1 and CB2 receptors. Most of these compounds are N-piperidine-carboxamides that differ for R substituent (Cl, F, I, CH3, OCH3), whereas G, quite often, maintained the 2,4-Cl-phenyl substitution pattern of rimonabant [23].
Compounds I were synthesized starting from the appropriate ketones 1 (Scheme 1) which were α-acylated by Claisen reaction, furnishing 1,3-diketoesters 2 as a tautomeric equilibrium shifted towards the alkenylidene structure (2′). The cyclization with appropriate hydrazines in refluxing EtOH gave the tricyclic dihydroindeno(1,2-c)pyrazole esters 3, which were hydrolyzed with KOH, affording the corresponding acids 4. Target compounds I were synthesized by condensation of acids 4, previously activated to acyl chlorides with SOCl2, with the appropriate amines.
If not otherwise stated, the four-step general synthetic route for I compounds, with minor changes, was employed for the preparation of all compounds of general formula II-XVII, starting from the appropriate ketones and using the appropriate hydrazines and amines.
Our first SAR study revealed that several compounds incorporating the planar 1,4-dihydroindeno(1,2-c)pyrazole scaffold displayed very high in vitro binding affinity for CB2 receptors comparable to, or exceeding, that of SR144528 (Figure 1), identified as the first highly potent and selective ligand for the CB2 receptors. Representative derivatives are IAaX, IAhX, IAfX, IBaX (Figure 3), compound IAhX emerging for its high affinity for CB2 receptors and exceptional selectivity over CB1 receptor (CB1/CB2 selectivity ratio of 9811).
Our results prompted us to investigate new 1,4-dihydroindeno(1,2-c)pyrazoles (I), which were obtained modifying the N-carboxamide moiety (Q) and the aryl substitution of the lead compounds IAaX and IAhX [24]. In general, our SAR study showed that the CB1 receptor affinities of all the investigated compounds were lower than their CB2 receptor affinities, evidencing the suitability of 1,4-dihydroindeno(1,2-c)pyrazole architecture to generate ligands for CB2 receptor interaction. Representative compounds of this series are IDhX, IEhX, IFhX, IGhX (Figure 4), all displaying high CB2 affinity and reasonable selectivity over CB1 receptors, even if lower than that elicited by compounds IAaX and IAhX.
In vitro CB2 intrinsic activity evaluation assay, based on the determination of P-ERK 1/2 increasing expression in human promyelocitic leukemia HL-60 cells exposed to the compounds to be assayed, highlighted agonist activity toward CB2 receptors for derivatives IDhX, IEhX and for prototype IAaX, IAhX. In particular, the tested compounds significantly increased P-ERK 1/2 expression, reaching the maximum effect at the concentration of 10 nM with the following values: +61.3 ± 12.4% (IDhX), +125.0 ± 35.8% (IEhX), +65.0 ± 18.5% (IAaX), +83.0 ± 4.2% (IAhX) versus vehicle. Overall, the effect of tested compounds as CB2 agonists was specific as it was blocked by the CB2 receptor antagonist SR144528 [24].
By pursuing our interest in expanding SAR studies around 1,4-dihydroindeno(1,2-c)pyrazole core, especially in the light of the potential of CB2 ligands for the treatment of immune disorders or as anti-nociceptive agents [14,25], novel derivatives have been designed, making use of molecular hybridization based on scaffold hopping [26]. In particular, based upon the putative interacting sites and structural features of selective CB2 antagonist SR144528 (Figure 1), i.e., N1-benzyl group, the C3 carboxamide moiety, and the substitution of the C5 phenyl ring [26,27], it was postulated that the introduction of such pharmacophoric elements in the tricyclic core of compound IAhX might provide new CB2 ligands with potential therapeutic value. Briefly, different synthesized compounds were monoterpene derivatives incorporating bulky groups in the carboxamide moiety (i.e., fenchyl-, bornyl-, isopinocampheyl-, myrtanyl-, menthyl-), bearing a 6-CH3,7-Cl or 6-Cl,7-CH3 substitution pattern at the aryl ring of 1,4-dihydroindeno(1,2-c)pyrazole core. Some adamantane derivatives were also investigated, together with compounds incorporating simple cycloalkyl motifs at the carboxamide moiety. Compounds IAjX, IAkX, IHjX, IIjX, IKjX, IDjX, IDkX, IHkX (Figure 5) are representatives of these third series of I compounds. As described above for representative compounds depicted in Figure 3 and Figure 4, our SAR study carried out on a third series of molecules, evidenced for 1,4-dihydroindeno(1,2-c)pyrazole-based molecules preferential affinity for CB2 receptors. However, the introduction of a chlorine atom, as well as its exchange with the methyl group in all-new hybrid compounds seemed to play a modest role in lowering the levels of CB2-affinity as compared to the reference compounds IAaX and IAhX.
According to previous data obtained for compounds IAaX, IAhX, IDhX and IEhX, analogs IIjX, IDjX and IHkX, endowed with the highest affinity for CB2 receptors, exhibited CB2 agonism activity in in vitro model based on the determination of P-ERK 1/2 increasing expression in HL-60 cells, with maximum values reached at 125 nM for compounds IIjX (+54.5 ± 12.1%) and IDjX (+82.5 ± 19.1%), and at 50 nM for compound IHkX (+46.4 ± 15.6%) versus vehicle. Furthermore, the effect of such tested compounds on P-ERK ½ expression was counteracted by the reference CB2 antagonist AM630, suggesting the correspondence between the detected effect and CB2 modulation.
The obtained data confirmed that the flattening of 1,4-dihydroindeno(1,2-c)pyrazole core is important to assure agonist rather than antagonist activity, with respect to not condensed and more flexible analogs such as the antagonist SR144528.
Within this frame, a series of compounds incorporating the 1,4-dihydroindeno(1,2-c)pyrazole scaffold (I), sharing the N1-benzyl group and bulky groups in the carboxamide moiety (i.e., IOkW, Figure 2) were claimed by Sanofi-Aventis, but no specific biological activity was presented [28]. However, the compounds of the invention were generally described as potent and selective CB2 receptor antagonists with Ki values < 5 × 10−7 M. Antagonistic properties of such compounds have been demonstrated by the results in the models for inhibition of adenylate cyclase induced by forskolin, although no specific examples or data were disclosed.
Furthermore, 1,4-dihydroindeno(1,2-c)pyrazoles featuring a cyclopropyl or cyclohexyl building block in C6 position were investigated by us, in order to evaluate the effect of cycloalkyl moiety in place of methyl group both on cannabinoid receptor binding and activity [29]. The most interesting compounds coming from this fourth series are depicted in Figure 6. Whereas, these analogs provided further insight regarding the structural features for CB2 affinity and selectivity, our data evidenced that the introduction of a cyclopropyl moiety in most of the synthesized compounds seemed to play a modest role in lowering the CB2 receptor affinity, especially if compared to compound IAhX. Interestingly, intrinsic activity for compounds IAlX, IHlX, ILlX, IJlX, evaluated by GTPγS binding assay, showed antagonist/inverse agonist properties (IC50 for compound IAlX = 294 nM, for IHlX = 80 nM, for ILlX = 27 nM and for IJlX = 51 nM).
Independently, other groups investigated the biological properties of some 1,4-dihydroindeno(1,2-c])pyrazoles synthesized by our group. In particular, within the search aiming to characterize the molecular pharmacology of the most widely used CB2 receptor ligands, it was reported for compound IAhX, namely Gp-1a, an affinity for the CB2 receptors markedly different from that reported by our group (Ki CB1 = 426 ± 0.08 nM, Ki CB2 = 20.9 ± 0.23 nM; CB1/CB2 selectivity ratio = 20), using (3H)CP-55,940 and mouse brain and spleen as source for CB1 and CB2 receptors, respectively [30]. Furthermore, in contrast to our results, the same authors reported for Gp-1a inverse agonist properties on CB2 receptors in GTPγS assay and resulted not active in hCB2 receptor pERK assay [30]. Indeed, the first two series of 1,4-dihydroindeno(1,2-c)pyrazole-based compounds synthesized by our group [23,24], including Gp-1a, were described in a patent application providing methods and pharmaceutical compositions for reducing the serum level of immunoglobulin IgE in an animal or human subject [31]. In particular, it was reported the CB2 agonist Gp-1a attenuated the serum levels of total IgE from BALB/e mice and the co-treatment with the CB2 antagonist SR144528 reversed the Gp-1a effect. Therefore, the patent provided a method for modulating this type of antibody for the treatment of immune system-related conditions such as allergy, hay fever and the like. Biological literature concerning Gp-1a pointed out the relevance of such a compound as a useful pharmacological tool to ascertain in more detail the role of CB2 receptors in physiopathological conditions [32,33,34,35,36]. Furthermore, the pharmacological relevance of 1,4-dihydroindeno(1,2-c)pyrazole-based I compounds emerged also from the significant anti-nociceptive activity of the potent and selective CB2 agonist IDhX, namely NESS400, in Spared Nerve Injury (SNI) neuropathic mice, by alleviating both mechanical allodynia and thermal hyperalgesia [37].

2.2. Benzofuro(3,2-c)pyrazol-Based Derivatives (V)

Further condensed (5,5)-pyrazole derivatives were designed by us making use of bioisosteric replacement as drug design approach to obtain novel planar tricyclic scaffold for cannabinoid receptor interaction [38]. Following this approach, a new series of 1,4-dihydroindeno(1,2-c)pyrazole analogs, namely benzofuro(3,2-c)pyrazoles (V, Figure 2), containing an oxygen atom at position 4 instead of a methylene unit, were designed. The structure of representative compounds is depicted in Figure 7. These compounds were previously described by Neuroscienze Pharmaness S.C.A.R.L in a patent application claiming specific composition of microemulsions of pharmaceutical compounds. Indeed, the patent covers a more extensive series of tricyclic pyrazoles belonging both to (5,5) as well as (5,6) and (5,7]) series [39].
In general, our SAR study revealed high CB2 receptor affinity for the new compounds, with values qualitatively similar with those of compound IDhX, as well as those of related analogs incorporating the 1,4-dihydroindeno(1,2-c)pyrazole skeleton. In contrast, a comparison of KiCB2 value of compound IAhX and that of the analog VAhX revealed two orders of magnitude decreased affinity for VAhX. Compounds VLhX and VMhX, featuring a bornyl and isopinocampheyl moiety at the carboxamide portion, exhibited the best CB2 cannabinoid binding profiles among all synthesized derivatives. CB2 functional assay carried out on HL-60 cells, based on the evaluation of P-ERK1/2 expression induced by cannabinoid ligands, evidenced agonism behavior for all synthesized compounds [38], with calculated maximum values, in most cases, exceeding that of the agonist WIN-55,212-2 (i.e., VAhX: dose 50 nM, 205 ± 12%; VDhX, dose 50 nM, 196 ± 20%; VLhX: dose 10 nM, 189 ± 11%; VMhX: dose 5 nM, 205 ± 6%; WIN-55,212-2: dose 75 nM, 190 ± 17% versus vehicle). Overall, the effect of tested compounds as CB2 agonists was specific as it was blocked by the CB2 receptor antagonist AM630 [38].

2.3. 1,4-Dihydrothieno(2′,3′-4,5)cyclopenta(1,2-c)pyrazole-Based Derivatives (VII) and 1,4-Dihydrothieno(3′,2′-4,5)cyclopenta(1,2-c])pyrazole-Based Derivatives (X)

To further investigate the versatility of (5,5)-pyrazole condensed tricyclic derivatives in the development of CB2 ligands as therapeutic agents, our attention was focused on the benzene ring of the tricyclic indenopyrazole scaffold (I), by replacing it with a thiophene ring, giving rise the novel dihydrothienocyclopentapyrazole architecture which fine-tuning furnished novel derivatives with general formula VII (Figure 2). It was postulated that bioisosteric replacement benzene/thiophene could be an efficient strategy to develop novel CB2 selective ligands and maybe provide further insight concerning structural features for cannabinoid receptor interaction [40]. In our SAR study, we planned to investigate the effect of changing the size of carboxamide moiety (Q), of methyl shifting from C6 to C7 of the tricyclic platform, as well as the effect related to the replacement of the N1-dichlorophenyl group (X) with p-methylbenzyl moiety (Z) on cannabinoid receptor affinity. The structure of representative compounds is depicted in Figure 8. The major term, compound VIIAhX, displayed a high affinity for CB2 receptors, even if 62-fold decreased with respect to the reference compound IAhX with selectivity ratio Ki CB1/Ki CB2 = 191. A similar trend was observed in several thienocyclopentapyrazole compounds (Figure 8) with the exception of VIINhX, which exhibited a mixed binding profile, reaching Ki values of 6.5 and 5.1 nM for CB1 and CB2, respectively. All these compounds profiled as full agonists at CB2 receptors in an assay based on the determination of P-ERK 1/2 increasing expression in HL-60 cells [40].
Within this framework, a series of 1,4-dihydrothieno(3′,2′-4,5)cyclopenta(1,2-c)pyrazole-based derivatives with general formula X (Figure 2) were investigated. Representative compounds are depicted in Figure 9. Such compounds were described by Neuroscienze Pharmaness S.C.A.R.L in a patent application encompassing a more extensive series of condensed tricyclic pyrazoles [41]. According to binding data, shifting the sulfur atom of the 1,4-dihydrothieno(2′,3′-4,5)cyclopenta(1,2-c)pyrazole structural template from position 5 to 7 induced a significant impact on cannabinoid receptor affinity. In general, most of the investigated compounds exhibited a preferential affinity for CB2 receptors, with different compounds showing mixed and high CB1/CB2 cannabinoid receptor affinities (XIhZ, XNhZ, XHhX, XIhY, XIhX, XIgX, Figure 9).
Amongst the compounds claimed in the patent application, derivatives XIhZ, XNhZ, XHhX were investigated to evaluate their intrinsic activity as agonist or antagonist on CB1 receptors in an ex-vivo model based on the use of the vas deferens. According to the behavior of WIN-55,212-2 and other CB1 ligands in mice vas deferens isolated organ assay [42], compounds XIhZ, XNhZ, XHhX showed agonist activity, with XIhZ the most effective in inhibiting the contractions induced by an electric stimulus compared to the basal value, as evidenced by the reported dose-response curve [41].
Compounds XIhZ, XNhZ, XHhX were also investigated for their ability to reduce intraocular pressure (IOP) which is considered a prominent risk factor for glaucoma development and progression [43]. The first study highlighting the relevance of CB1/CB2 agonists for the treatment of glaucoma was conducted in 1971, reporting that smoking marijuana significantly lowered the IOP [44]. Very positive results were reported also for WIN-55,212-2, which is the prototype of the aminoalkylindole class of synthetic cannabinoids, activating both CB1 and CB2 receptors, albeit with a proclivity for the CB2 receptors. In particular, in normotensive rabbits, a single dose of WIN-55,212-2, either topical or systemic, significantly reduced IOP without apparent ocular toxicity, most likely through effects on CB1 receptors [45]. Subsequent studies showed a reduction of IOP in glaucomatous rats after local and chronic administration of WIN-55,212-2, without adverse effects [46]. These findings are consistent with another experiment showing that WIN-55,212-2 decreased IOP in human glaucoma resistant to conventional therapies [47]. Further studies have demonstrated increased aqueous outflow after exposure to the CB2 agonist JWH015, suggesting a beneficial function derived from CB2 receptor activation in the treatment of ocular diseases such as glaucoma [48]. Neuroprotective properties of cannabinoids have been demonstrated in CNS neurodegenerative diseases with different mechanisms [49]. Several studies have shown in the retina that CB1 agonists (Δ9-tetrahydrocannabinol and cannabidiol) protected ganglion cells from glutamate-excitotoxicity and ischemia caused by increased IOP [50,51]. Although all these data are promising, an important issue for the clinical potential of cannabinoids as anti-glaucoma agents has been cardiovascular and psychotropic side effects mediated by systemic and brain cannabinoid receptor activation [52,53,54]. Additionally, short duration of action of cannabinoids on IOP reduction (i.e., the duration of action after smoking marijuana is only 3–4 h) is another issue that has to be overcome in the application of these compounds in treating glaucoma. Actually, standard therapeutic options in treating glaucoma include a few IOP-lowering drugs as prostaglandin analogs, β-adrenoreceptor antagonists, α2-adrenoreceptor agonists, carbonic anhydrase inhibitors, and cholinergic agonists [55]. When medical therapy failed to lower IOP, laser or surgical interventions are extremely considered in order to prevent disease progression toward blindness.
According to unmet medical need, compounds XIhZ, XNhZ, XHhX, exhibiting high and mixed CB1/CB2 receptor affinities, with a proclivity for CB2 subtype, and endowed of CB1 agonist properties, according to the CB receptor profile of the reference cannabinoidergic compound WIN-55,212-2, by using the animal model of old DBA/2J mice, were investigated for their ability to reduce IOP [41]. Compounds XIhZ, XNhZ, XHhX and WIN-55,212-2, which was used as reference compound, were dispersed in the commercial emulsion Tocrisolve™ and applied to the eye of old DBA/2J mice at a concentration of 100 µg or 50 µg. The obtained results, reported in Table 1, showed that commercial emulsion Tocrisolve™ (20, 40 µL) had no effect on the IOP. Furthermore, at the dose of 100 µg, all tested compounds were effective in reducing eye pressure as the reference compound WIN-55,212-2, while only XIhZ, at the dose of 50 µg was more effective in reducing IOP than the reference compound. What is claimed in the patent application was pharmaceutical compositions comprising emulsions or microemulsions may be useful to avoid systemic side effects of such cannabinoid compounds. The preliminary results reported in the patent application [41] for compound XIhZ could pave the way for the development of novel cannabinoidergic compounds as anti-glaucoma agents.

2.4. 1,4-Dihydropyrazolo(3,4-a)pyrrolizine-Based Derivatives (XV)

Continuing with our interest in expanding SAR studies on cannabinoid receptors, and taking into consideration the binding profile of compounds IAaX and IAhX, a new tricyclic pyrazole scaffold, namely 1,4-dihydropyrazolo(3,4-a)pyrrolizine XV, was designed on the basis of bioisosteric replacement approach (benzene/pyrrole) [56]. Representative compounds are depicted in Figure 10. Surprisingly, none of the new compounds exhibited a high affinity for CB2 receptors, with Ki values above 314 nM. Negligible affinity was also determined for CB1 receptors, with XVIhX reaching the Ki value of 142 nM.

3. (5,6)-Condensed Pyrazole Derivatives

3.1. 4,5-Dihydro-1H-benzo(g)indazole-Based Derivatives (II)

The first (5,6)-condensed pyrazole derivatives synthesized by us are those of general formula II (Figure 2), featuring the 4,5-dihydro-1H-benzo(g)indazole scaffold which is a homologue of 1,4-dihydroindeno(1,2-c)pyrazole one (compounds I). Representative compounds are depicted in Figure 11 [57]. Most of such compounds were described by Sanofi-Aventis in a patent application as cannabinoid CB1 receptor antagonists, but no biological data were reported [58].
Interestingly, as evidenced by Ki values of compounds IIAbX and IIAiX with respect to compounds IAaX and IAhX, increasing the carbocyclic central ring size by one methylene unit (from (5,5)- to (5,6)-condensed pyrazole derivatives) involved a marked loss of affinity for CB2 receptors, a significant increase in CB1 affinity, and a consequent loss of CB2 selectivity. A similar trend was exhibited by other derivatives incorporating such 4,5-dihydro-1H-benzo(g)indazole scaffold (i.e., IIAeX and IIBbX). The SAR study carried out on the two homologous series I and II, prompted us to suppose that to achieve high binding affinity to CB1 receptors and CB1 over CB2 selectivity it is important for the tricyclic system to be non-planar. To evaluate the functional profile, several compounds were assayed for the capability to affect gastrointestinal transit in mice, making use of the upper gastrointestinal test which is based on the determination of the intestinal length traveled by a non-absorbable marker as a consequence of the active compound administration. From this test, compound IIAbX was able to induce a dose-dependent gastrointestinal motility increase, as well as compound IIAiX. This effect was markedly reversed by the in vivo administration of CP-55,940, suggesting for the series of 4,5-dihydro-1H-benzo(g)indazole-3-carboxamides antagonistic profile for CB receptors [57].

3.2. 4,5-Dihydro-1H-thieno(2,3-g)indazole-Based Derivatives (VIII) and 4,5-Dihydro-1H-thieno(3,2-g)indazole-Based Derivatives (XI)

A number of compounds sharing a 4,5-dihydro-1H-thieno(2,3-g)indazole scaffold (VIII), which is a homolog of the previously-described 1,4-dihydrothieno(2′,3′-4,5)cyclopenta(1,2-c)pyrazole one (VII) were claimed by Neuroscienze Pharmaness S.C.A.R.L. [59]. The structure of representative compounds and CB1/CB2 receptor affinity values are reported in Figure 12. According to binding data, most compounds exhibited a potent and mixed CB1/CB2 binding profile, with a proclivity for CB1 receptors. The thieno(2,3-g)indazole-based derivative VIIIAeX resulted in the most selective for CB1 receptors between all reported compounds. The disclosed compound VIIIAeX, namely NESS038C6, highlighted CB1 antagonism behavior by both in isolated organ assays and in vivo tests based on rat intestinal motility (data not shown). Chronic treatment with NESS038C6 in C57BL/6N diet-induced obesity (DIO) mice determined a significant reduction of weight which was comparable to that detected in DIO mice treated with SR141716 [60]. The Neuroscienze Pharmaness S.C.A.R.L. patent [59] encompasses also a series of isomeric compounds incorporating the 4,5-dihydro-1H-thieno(3,2-g)indazole scaffold XI (i.e., XIAbX, Figure 2) and others, but not cannabinoid binding receptor affinity was reported.

3.3. 1,5-Dihydroisothiochromen([4,3-c)pyrazole-Based Derivatives (XIII) and 1,4-Dihydrothiochromeno(4,3-c)pyrazole-Based Derivatives (XIV)

A series of derivatives featuring a 1,5-dihydroisothiochromeno(4,3-c]pyrazole- and 1,4-dihydrothiochromeno(4,3-c)pyrazole-scaffolds, XIII and XIV, respectively (i.e., XIIIBbX or XIVAbX, Figure 2) were claimed by Sanofi-Aventis for cannabinoid receptor interaction, but no biological activity was presented [58].

3.4. 4,5-Dihydro-1H-Pyrazolo(4,3-g)indolizine-Based Derivatives (XVI)

To further extend SAR study on cannabinoid receptors, and driven by the negligible results on CB1/CB2 receptor affinity of 1,4-dihydropyrazolo(3,4-a)pyrrolizines (XV), homologue 4,5-dihydro-1H-pyrazolo(4,3-g)indolizines (XVI, Figure 2) have been synthesized [56]. Representative compounds are depicted in Figure 13. According to binding data reported for compounds XVIAbX, XVICbX, XVIDbX with respect to compounds XVAaX, XVAhX, XVIaX, XVIhX, the expansion of the central ring size by a methylene unit led to conformational changes that promote the affinity for CB1 receptors and improve CB2/CB1 selectivity ratio, with XVICbX reaching reasonable affinity for CB1 receptors (Ki CB1 = 81 nM) and the highest CB2/CB1 selectivity ratio (>12).

4. (5,7)-Condensed Pyrazole Derivatives

4.1. 1,4,5,6-Tetrahydrobenzo(6,7])cyclohepta(1,2-c]pyrazole-Based Derivatives (III)

The intriguing SAR study carried out on ligands with the 1,4-dihydroindeno(1,2-c)pyrazole core (i.e., IAaX, IAhX) endowed with very high binding affinity for CB2 receptors in comparison to homologous ligands having 4,5-dihydro-1H-benzo(g)indazoles (i.e., IIAbX, IIAiX) exhibiting higher CB1 binding affinity, prompted us to design and synthetize a new homologous series of general formula III, incorporating 1,4,5,6-tetrahydrobenzo(6,7)cyclohepta(1,2-c)pyrazole scaffold, for cannabinoid receptor interaction [61]. Representative compounds are depicted in Figure 14. Compound IIIAcX, namely NESS0327, was first claimed by Sanofi-Aventis, but no biological data was presented in the patent [58].
In general, all the investigated compounds exhibited preferential affinity for CB1 receptors, with NESS0327, endowed of Ki CB1 = 4.2 nM, Ki CB2 = 55.7 nM and Ki CB2/Ki CB1 selectivity ratio = 13.26. Slightly different values for CB1 receptors, possibly due to different receptor matrix, were reported for IIIAcX by two other independent groups: Stoit et al. Ki CB1 = 126 nM [62] and Zhang et al. 18.4 nM [63] using (3H)-CP 55,940 and hCB1 receptor cloned in CHO cells or membranes isolated from a HEK-293 expression system, respectively. Compound IIIIcX, bearing the bulky myrtanil substituent, showed the best CB1 receptor affinity which was equivalent to that exhibited by IIIAcX. Moving the chlorine atom from position 8 to 9 of the myrtanil-based derivative IIIIcX to give IIIIdX induced a decrease of CB1 receptor affinity with a concurrent loss of selectivity. CB1 receptor intrinsic activity of selected derivatives was evaluated through in vitro tests based on the determination of phosphorylated ERK 1/2 (P-ERK 1/2) expression in mouse neuroblastoma N1E-115 cell line. According to rimonabant, compounds IIIAcX and IIIBcX didn’t affect P-ERK expression in N1E-115 cells in the concentration range 1 nM-10µM; P-ERK 1/2 (% of vehicle): vehicle, 100 ÷ 10; rimonabant (1 µM): 110 ÷ 8; IIIAcX (1 µM): 111 ÷ 12; IIIBcX (1 µM): 95 ÷ 9. Furthermore, these compounds inhibited the P-ERK 1/2 expression up-regulation induced by the reference cannabinoid agonist WIN-55,212-2; vehicle: 185 ÷ 12; rimonabant (1 µM): 108 ÷ 7; IIIAcX (1 µM): 115 ÷ 13; IIIBcX (1 µM): 103 ÷ 9. In contrast, the myrtanil-based derivatives IIIIcX and IIIIdX enhanced P-ERK 1/2 expression in N1E-115 cells, highlighting CB1 receptor agonism profile for both compounds [61]. The pharmacological relevance of 1,4,5,6-tetrahydrobenzo(6,7)cyclohepta(1,2-c)pyrazole-based derivatives III emerged from the ability of antagonist NESS0327 to induce reduction of weight gain and food intake equivalent to that of rimonabant [64]. Furthermore, it was reported that the neutral antagonist profile exhibited by NESS0327 appeared important to avoid the side effects induced by rimonabant administration (i.e., suppression of the constitutive CB1 receptor activity in the ventral tegmental area and basolateral amygdala causing anxiety and reduced motivation for reward). Several patents testify to the pharmaceutical interest of NESS0327 [65,66,67,68]. Within this frame, the University of Queensland claimed method and agents for reducing general anesthetic induced neuroexcitation, attributing such side effect especially to neurosteroid general anesthetic agents as alfaxalone, even if the patent covers all general anesthetics in use [69]. In vitro electrophysiological analysis showed alfaxalone significantly decreased the amplitude of inhibitory synaptic currents (IPSC) on hypoglossal motor neurons, at a concentration ranging between 100 nM to 10 µM, consistent with increased in vivo motor activity and muscle twitching induced by alfaxalone. Treatment of hypoglossal motor neurons with NESS0327 was demonstrated to attenuate the effect of alfaxalone both on evoked than spontaneous IPSC amplitude. In vivo analysis conducted on Wistar rats highlighted administration of NESS0327 as a premedication prior to alfaxalone anesthesia significantly reduced muscle twitching during the induction and recovery phases of anesthesia. More importantly, premedication with NESS0327 had no detrimental effect on arterial O2 saturation or respiration rate during alfaxalone anesthesia [69].

4.2. 4,5-Dihydro-1H-benzo(2,3)oxepino(4,5-c)pyrazole-Based Derivatives (VI)

Endocannabinoids are orexigenic factors promoting appetite via CB1 receptor activation. This finding provided the rationale for the development of CB1 antagonist/inverse agonist rimonabant for obesity treatment and its metabolic complications. However, rimonabant side effects responsible for its withdrawal were principally related to both activities on SNC and to inverse agonism profile [70,71]. Therefore, new strategies have been proposed for the development of more safe anti-obesity agents, such as the identification of peripherally restricted CB1 receptor antagonists [71] as well as neutral CB1 receptor antagonists or CB1 allosteric modulators [72]. Within this frame, it was envisioned that bioisosteric modification of 1,4,5,6-tetrahydrobenzo(6,7)cyclohepta(1,2-c)pyrazole core (III) might offer new templates for CB1 receptor interaction. Thus, a series of 4,5-dihydro-1H-benzo(2,3)oxepino(4,5-c)pyrazoles (VI, Figure 2), containing an oxygen atom at position 6 in place of a methylene unit, were designed and synthesized. Such bioisosteric methylene/oxygen replacement might give access to CB1 ligands with increased polar surface area and decreased lipophilicity, which were considered critical parameters to influence the blood-brain permeability. Representative compounds are VIAcX, VIDcX, VIIcX (Figure 15), all exhibiting nanomolar/near nanomolar affinity for CB1 receptors [73]. Within this frame, a series of compounds sharing a 4,5-dihydro-1H-benzo(2,3)oxepino(4,5-c)pyrazole core, including VIAcX, were claimed by Cadila Healthcare Limited, but no binding data for cannabinoid receptors were presented [74]. However, the compounds of the invention were generally said, in the cAMP accumulation model, to antagonizes the WIN-55,212-2 inhibition of forskolin-induced cAMP accumulation in hCB1 CHO cells. Furthermore, VIAcX, and other representative compounds have been shown to reduce, in the sucrose solution intake rat model, the sucrose solution consumption [74,75]. In our hands, compound VIAcX, namely NESS06SM, emerged for its nanomolar CB1 receptor affinity and good selectivity with respect to CB2 one (Ki CB1 = 10.25 nM, Ki CB2 > 5000 nM). Evaluation of intrinsic activity carried out on NESS06SM highlighted a neutral antagonist profile both in (35S)GTPγS assay and in isolated organ assays (mouse vas deferens) [76]. In silico parameters (cLogPOW, tPSA, log BB), compared with IIIAcX (NESS0327) and other already known CB1 antagonists (i.e., rimonabant), suggested that NESS06SM exhibited sparing BBB permeability. Moreover, chronic treatment with NESS06SM resulted in the reduction of body weight and cardiovascular risk factor improvement in C57BL/6N diet-induced obesity (DIO) mice fed with a fat diet. Furthermore, in contrast to rimonabant, the chronic treatment of NESS06SM did not change mRNA expression of both monoaminergic transporter and neurotrophins, highly related to anxiety and mood disorders [76]. Interestingly, the co-treatment of NESS06SM has been shown to reduce food intake and weight gain, mitigate the side effects induced by chronic administration of the atypical antipsychotic olanzapine, without altering the positive effects of olanzapine on behavior [77].
As expected, evaluation of the intrinsic activity of VIDcX, namely SM-11, evidenced CB1 antagonist activity, both in in vitro test (P-ERK 1/2 expression in N1E-115 cells) and in isolated organs (mouse vas deferens). Behavioral studies highlighted that dose-dependently SM-11 decreased food intake in rats by 15–20%. Moreover, the i.v. administration of SM-11 fully and readily antagonized the effect of the agonist WIN-55,212-2 on the activity of ventral tegmental area (VTA) dopamine neurons projecting to the nucleus accumbens cells, confirming its antagonist profile. Furthermore, this data supported that SM-11 can lessen the hedonic aspect of food thus promoting bodyweight reduction [78].

4.3. 1,4,5,6-Tetrahydrothieno(2′,3′-6,7])cyclohepta(1,2-c)pyrazole-Based Derivatives (IX) and 1,4,5,6-Tetrahydrothieno(3′,2′-6,7)cyclohepta(1,2-c)pyrazole-Based Derivatives (XII)

A series of derivatives incorporating a 1,4,5,6-tetrahydrothieno(2′,3′-6,7)cyclohepta(1,2-c)pyrazole- and 1,4,5,6-tetrahydrothieno(3′,2′-6,7)cyclohepta(1,2-c)pyrazole-scaffolds IX and XII, respectively, (i.e., IXAcX or XIIAcX, Figure 2) were claimed by Neuroscienze Pharmaness S.C.A.R.L. for cannabinoid receptor interaction, but no biological activity was presented [59].

4.4. 1,4,5,6-Tetrahydropyrazolo(3,4-c)pyrrolo(1,2-a)azepine-Based Derivatives (XVII)

A series of 1,4,5,6-tetrahydropyrazolo(3,4-c)pyrrolo(1,2-a)azepine-based derivatives (XVII, Figure 2) has been investigated for cannabinoid receptor interaction [56]. Representative compounds are depicted in Figure 16, all devoid of affinity for CB2 receptors and endowed of negligible affinity for CB1 receptors.

5. (5,8)-Condensed Pyrazole Derivatives

4,5,6,7-Tetrahydro-1H-benzo(7,8)cyclooct(1,2-c)pyrazole-Based Derivatives (IV)

Zhang et al. described the synthesis and biological evaluation of a series of conformationally constrained analogs of rimonabant [63]. Within this frame, they synthesized both compound IIIAcX from our lab and IVAdX (Figure 17) which is the only pyrazole-based tricyclic compound known belonging to (5,8)-condensed derivatives, featuring the 4,5,6,7-tetrahydro-1H-benzo(7,8)cycloocta(1,2-c)pyrazole core. The compound, endowed of lower affinity for CB2 than CB1 receptors, exhibited a similar trend with respect to homologous compounds IIAbX and IIIAcX. However, increasing the carbocyclic central ring size by one methylene unit, i.e., from (5,7)- to (5,8)-condensed pyrazole derivatives, involved a marked loss of affinity for CB1 receptors.

6. Miscellaneous Derivatives

Other pyrazole-based tricyclic derivatives, featuring the pyrazolo(5,1-f)(1,6)naphthyridine core (Figure 18), were investigated for cannabinoid receptor interaction [79].
The pyrazolo(5,1-f)(1,6)naphthyridine derivatives were synthesized making use of AgOTf and proline-cocatalyzed multicomponent methodology (Scheme 2), starting from the appropriate o-alkynylaldehydes 9, p-toluenesulfonyl hydrazide (PTSH) and ethyl pyruvate, to gave key pyrazole-esters 10 which, hydrolyzed with NaOH, afforded the corresponding acids 11. Target compounds were synthesized by condensation of acids 11, previously activated with pivaloyl chloride, with the appropriate amines. The o-alkynylaldehydes 9 were obtained from 2-bromonicotinaldehyde 8 and appropriate alkynes which were reacted under the conventional Sonogashira conditions.
Compounds 5–7 exhibited affinity levels for CB2 receptors in the near nM range (Ki: 33–67 nM) with a good degree of selectivity for CB2 receptors compared to CB1. According to in vitro assays based on the effects of forskolin-stimulated cAMP levels in human CB2 CHO cells, compounds 5–7 exhibited antagonist/inverse agonist properties [79].

7. Conclusions

In the last decades, the CB1 antagonist/inverse agonist rimonabant has been considered an extremely valuable lead for the design of new ligands for CB receptors interaction, with potential therapeutic value. In the context of this review, the introduction of structural constraints in rimonabant, the use of medicinal chemistry approaches as homologation or bioisosterism, gave access to several compounds most of which belong to (5,5), (5,6) and (5,7)-condensed tricyclic pyrazole derivatives. Here we have summarized the extensive SAR studies carried out on such compounds, allowing us to identify different ligands endowed with high affinity and selectivity for CB1 or CB2 receptors. In particular, the pharmacological relevance of 1,4-dihydroindeno(1,2-c)pyrazole-based I compounds, belonging to (5,5) tricyclic pyrazole derivatives, emerged from the significant anti-nociceptive activity of the potent and selective CB2 agonist IDhX, by alleviating both mechanical allodynia and thermal hyperalgesia in Spared Nerve Injury (SNI) neuropathic mice. The interest of ligands belonging to (5,5) tricyclic pyrazole derivatives emerged also for their potential as anti-glaucoma agents, for the ability to reduce intraocular pressure (IOP). Compound XIhZ, featuring the 1,4-dihydrothieno(3′,2′-4,5)cyclopenta(1,2-c)pyrazole core and exhibiting high and mixed CB1/CB2 receptor affinities, effectively reduced intraocular pressure in the animal model of old DBA/2J mice, providing a potential alternative to the use of WIN-55,212-2 and smoking marijuana, known for their IOP lowering properties. SAR study pointed out the relevance of ligands belonging to (5,7) tricyclic pyrazole derivatives, for their anti-obesity potential. In this frame, the selective CB1 ligand VIAcX, featuring the 4,5-dihydro-1H-benzo(2,3)oxepino(4,5-c)pyrazole core, exhibiting neutral antagonist profile, effectively reduced body weight with the improvement of cardiovascular risk factor in C57BL/6N diet-induced obesity (DIO) mice fed with fat diet. Preliminary data evidenced the potentiality of compound VIAcX in the treatment of obesity with a more safe profile with respect to the antagonist/inverse agonist rimonabant.

Author Contributions

Conceptualization, B.A., and G.A.P.; methodology, G.M.; resources, P.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Università degli Studi di Sassari: fondo di Ateneo per la ricerca 2019, 2020.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Lambert, D.M.; Fowler, C.J. The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications. J. Med. Chem. 2005, 36, 5059–5087. [Google Scholar] [CrossRef]
  2. Pertwee, R. (Ed.) Cannabinoids; Springler: Berlin/Heidelberg, Germany, 2005. [Google Scholar]
  3. Pop, E. Cannabinoids, endogenous ligands and synthetic analogs. Curr. Opin. Chem. Biol. 1999, 3, 418–425. [Google Scholar] [CrossRef]
  4. Matsuda, L.A.; Lolait, S.J.; Brownstein, M.J.; Young, A.C.; Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346, 561–564. [Google Scholar] [CrossRef] [PubMed]
  5. Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nat. Cell Biol. 1993, 365, 61–65. [Google Scholar] [CrossRef]
  6. Herkenham, M.; Lynn, A.B.; Little, M.D.; Johnson, M.R.; Melvin, L.S.; de Costa, B.R.; Rice, K.C. Cannabinoid receptor location in brain. Proc. Natl. Acad. Sci. USA 1990, 87, 1932–1936. [Google Scholar] [CrossRef] [Green Version]
  7. Howlet, A.C. The CB1 cannabinoid receptor in the brain. Neurobiol. Dis. 1998, 5, 405–416. [Google Scholar] [CrossRef] [Green Version]
  8. Casu, M.A.; Porcella, A.; Ruiu, S.; Saba, P.; Marchese, G.; Carai, M.A.M.; Reali, R.; Gessa, G.L.; Pani, L. Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract. Eur. J. Pharmacol. 2003, 459, 97–105. [Google Scholar] [CrossRef]
  9. Glass, M. The role of Cannabinoids in neurodegenerative diseases. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2001, 25, 743–765. [Google Scholar] [CrossRef]
  10. Porcella, A.; Casellas, P.; Gessa, G.L.; Pani, L. Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: Implications for the antiglaucoma properties of marihuana. Mol. Brain Res. 1998, 58, 240–245. [Google Scholar] [CrossRef]
  11. Galiegue, S.; Mary, S.; Marchand, J.; Dussossoy, D.; Carriere, D.; Carayon, P.; Bouaboula, M.; Shire, D.; Fur, G.; Casellas, P. Expression of Central and Peripheral Cannabinoid Receptors in Human Immune Tissues and Leukocyte Subpopulations. Eur. J. Biochem. 1995, 232, 54–61. [Google Scholar] [CrossRef]
  12. Gong, J.-P.; Onaivi, E.S.; Ishiguro, H.; Liu, Q.-R.; Tagliaferro, P.A.; Brusco, A.; Uhl, G.R. Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. Brain Res. 2006, 1071, 10–23. [Google Scholar] [CrossRef]
  13. Lu, Q.; Straiker, A.; Lu, Q.; Maguire, G. Expression of CB2 cannabinoid receptor mRNA in adult rat retina. Vis. Neurosci. 2000, 17, 91–95. [Google Scholar] [CrossRef] [PubMed]
  14. Murineddu, G.; Asproni, B.; Pinna, G.A. A Survey of Recent Patents on CB2 Agonists in the Management of Pain. Recent Pat. Cns Drug Discov. 2012, 7, 4–24. [Google Scholar] [CrossRef] [PubMed]
  15. Marino, S.; Idris, A.I. Emerging therapeutic targets in cancer induced bone disease: A focus on the peripheral type 2 cannabinoid receptor. Pharmacol. Res. 2017, 119, 391–403. [Google Scholar] [CrossRef] [Green Version]
  16. Morales, P.; Blasco-Benito, S.; Andradas, C.; Gómez-Cañas, M.; Flores, J.M.; Goya, P.; Fernández-Ruiz, J.; Sánchez, C.; Jagerovic, N. Selective, nontoxic CB2 cannabinoid o-quinone with in vivo activity against triple-negative breast cancer. J. Med. Chem. 2015, 58, 2256–2264. [Google Scholar] [CrossRef] [Green Version]
  17. Yang, P.; Wang, L.; Feng, R.; Almehizia, A.A.; Tong, Q.; Myint, K.-Z.; Ouyang, Q.; Alqarni, M.H.; Wang, L.; Xie, X.-Q. Novel triaryl sulphonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: Discovery, optimization, and biological evaluation. J. Med. Chem. 2013, 56, 2045–2058. [Google Scholar] [CrossRef] [Green Version]
  18. Pertwee, R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 2009, 156, 397–411. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Mainolfi, N.; Powers, J.; Amin, J.; Long, D.; Lee, W.; McLaughlin, M.-E.; Jaffee, B.; Brain, C.; Elliott, J.; Sivak, J.M. An effective prodrug strategy to selectively enhance ocular exposure of a cannabinoid receptor (CB1/2) agonist. J. Med. Chem. 2013, 56, 5464–5472. [Google Scholar] [CrossRef]
  20. Pi-Sunyer, F.X.; Aronne, L.J.; Heshmati, H.M.; Devin, J.; Rosenstock, J.; for the RIO-North America Study Group. Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients. JAMA 2006, 295, 761–775. [Google Scholar] [CrossRef] [Green Version]
  21. Zhang, Y.; Seltzman, H.-H.; Brackeen, M.; Thomas, B.-F. Structure-Activity Relationships and Conformational Freedom of CB1 Receptor Antagonists and Inverse Agonists. In The Cannabinoid Receptors, 1st ed.; Reggio, P.H., Ed.; Humana Press: New York, NY, USA, 2009; pp. 95–119. [Google Scholar]
  22. Chang, C.-P.; Wu, C.-H.; Song, J.-S.; Chou, M.-C.; Wong, Y.-C.; Lin, Y.; Yeh, T.-K.; Sadani, A.A.; Ou, M.-H.; Chen, K.-H.; et al. Discovery of 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl) phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a novel peripherally restricted cannabinoid-1 receptor antagonist with significant weight-loss efficacy in diet-induced obese mice. J. Med. Chem. 2013, 56, 9920–9933. [Google Scholar]
  23. Mussinu, J.-M.; Ruiu, S.; Mulè, A.; Pau, A.; Carai, M.A.M.; Loriga, G.; Murineddu, G.; Pinna, G.A. Tricyclic pyrazoles. Part 1: Synthesis and biological evaluation of novel 1,4-dihydroindeno(1,2-c)pyrazol-based ligands for CB1 and CB2 cannabinoid receptors. Bioorg. Med. Chem. 2003, 11, 251–263. [Google Scholar] [CrossRef]
  24. Murineddu, G.; Lazzari, P.; Ruiu, S.; Sanna, A.; Loriga, G.; Manca, I.; Falzoi, M.; Dessì, C.; Curzu, M.M.; Chelucci, G.; et al. pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2′,4′-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno(1,2-c)pyrazole-3-carboxamide. J. Med. Chem. 2006, 49, 7502–7512. [Google Scholar] [CrossRef] [PubMed]
  25. Han, S.; Thatte, J.; Buzard, D.J.; Jones, R.M. Therapeutic Utility of Cannabinoid Receptor Type 2 (CB2) Selective Agonists. J. Med. Chem. 2013, 56, 8224–8256. [Google Scholar] [CrossRef]
  26. Murineddu, G.; Asproni, B.; Ruiu, S.; Deligia, F.; Falzoi, M.; Pau, A.; Thomas, B.F.; Zhang, Y.; Pinna, G.A.; Pani, L.; et al. Tricyclic pyrazoles. Part 5. Novel 1,4-dihydroindeno(1,2-c)pyrazolo CB2 ligands using molecular hybridization based on scaffold hopping. Open Med. Chem. J. 2012, 6, 1–14. [Google Scholar] [CrossRef] [Green Version]
  27. Kotsikorou, E.; Navas, F., III; Roche, M.J.; Gilliam, A.F.; Thomas, B.F.; Seltzman, H.H.; Kumar, P.; Song, Z.-H.; Hurst, D.P.; Lynch, D.L.; et al. The importance of hydrogen bonding and aromatic stacking to the affinity and efficacy of cannabinoid receptor CB2 antagonist 5-(4-chloro-3-methylphenyl)-1-((4-methylphenyl)methyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo(2.2.1)hept-2-yl)-1H-pyrazole-3-carboxamide (SR144528). J. Med. Chem. 2013, 56, 6593–6612. [Google Scholar] [PubMed] [Green Version]
  28. Barth, F.; Millan, J.; Oustric, D.; Rinaldi, M.; Vernhet, M. 1-Benzylpyrazole-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists. U.S. Pantent US6916838B1, 12 July 2005. [Google Scholar]
  29. Deiana, V.; Gómez-Cañas, M.; Pazos, M.R.; Fernández-Ruiz, J.; Asproni, B.; Cichero, E.; Fossa, P.; Muñoz, E.; Deligia, F.; Murineddu, G.; et al. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties. Eur. J. Med. Chem. 2016, 112, 66–80. [Google Scholar] [CrossRef]
  30. Soethoudt, M.; Grether, U.; Fingerle, J.; Grim, T.W.; Fezza, F.; de Petrocellis, L.; Ullmer, C.; Rothenhäusler, B.; Perret, C.; van Gils, N.; et al. Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nat. Commun. 2017, 8, 13958. [Google Scholar] [CrossRef]
  31. Klein, T.W.; Newton, C.; Patterson, C.; Agudelo, M. Methods and compositions for reducing serum levels of immunoglobulin E (IgE). WO2013/033155A1, 7 March 2013. [Google Scholar]
  32. Li, S.-S.; Wang, L.-L.; Liu, M.; Jiang, S.-K.; Zhang, M.; Tian, Z.-L.; Wang, M.; Li, J.-Y.; Zhao, R.; Guan, D.-W. Cannabinoid CB2 receptors are involved in the regulation of fibrogenesis during skin wound repair in mice. Mol. Med. Rep. 2016, 13, 3441–3450. [Google Scholar] [CrossRef] [Green Version]
  33. Naschi, M.; Hajikhani, M.; Ebrahimi, G.M.; Zarrindast, M.-R. Interaction between NMDA and CB2 function in the dorsal hippocampus on memory consolidation impairment: An isobologram analysis. Psychopharmacology 2017, 234, 507–514. [Google Scholar] [CrossRef] [PubMed]
  34. Xia, K.-K.; Shen, J.-X.; Huang, Z.-B.; Song, H.-M.; Gao, M.; Chen, D.-J.; Zhang, S.-J.; Wu, J. Heterogeneity of cannabinoid ligand-induced modulations in intracellular Ca2+ signals of mouse pancreatic acinar cells in vitro. Acta Pharmacol. Sinica 2019, 40, 410–417. [Google Scholar] [CrossRef]
  35. McBrinn, R.C.; Fraser, J.; Hope, A.G.; Gray, D.W.; Barratt, C.L.R.; da Silva, S.J.M.; Brown, S.G. Novel pharmacological actions of trequinsin hydrochloride improve human sperm cell motility and function. Br. J. Pharmacol. 2019, 176, 4521–4536. [Google Scholar] [CrossRef] [Green Version]
  36. Khakpai, F.; Ebrahimi-Ghiri, M.; Alijanpour, S.; Zarrindast, M.-R. Ketamine-induced antidepressant like effects in mice: A possible involvement of cannabinoid system. Biomed. Pharmacother. 2019, 112, 108717. [Google Scholar] [CrossRef]
  37. Luongo, L.; Palazzo, E.; Tambaro, S.; Giordano, C.; Gatta, L.; Scafuro, M.; Rossi, F.; Lazzari, P.; Pani, L.; De Novellis, V.; et al. 1-(2′,4′-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno(1,2-c)pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. Neurobiol. Dis. 2010, 37, 177–185. [Google Scholar] [CrossRef]
  38. Pinna, G.; Loriga, G.; Lazzari, P.; Ruiu, S.; Falzoi, M.; Frau, S.; Pau, A.; Murineddu, G.; Asproni, B.; Pinna, G.A. Tricyclic pyrazoles. Part 6. Benzofuro(3,2-c)pyrazoles: A versatile architecture for CB2 selective ligands. Eur. J. Med. Chem. 2014, 82, 281–292. [Google Scholar] [CrossRef]
  39. Lazzari, P.; Loriga, G.; Manca, I.; Pinna, G.A. Tricyclic pyrazole derivatives and microemulsions thereof as CB1- and/or CB2-inhibitors. EP2223913A1, 1 September 2010. [Google Scholar]
  40. Pinna, G.; Curzu, M.M.; Dore, A.; Lazzari, P.; Ruiu, S.; Pau, A.; Murineddu, G.; Pinna, G.A. Tricyclic pyrazoles part 7. Discovery of potent and selective dihydrothienocyclopentapyrazole derived CB2 ligands. Eur. J. Med. Chem. 2014, 85, 747–757. [Google Scholar] [CrossRef]
  41. Lazzari, P.; Loriga, G.; Manca, I.; Pinna, G.A. Pharmaceutical compounds. U.S. Patent US2010/0215759A1, 26 August 2010. [Google Scholar]
  42. Pertwee, R.G.; Stevenson, L.A.; Elrick, D.B.; Mechoulam, R.; Corbett, A.D. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br. J. Pharmacol. 1992, 105, 980–984. [Google Scholar] [CrossRef] [Green Version]
  43. Heijl, A.; Leske, M.C.; Bengtsson, B.; Hyman, L.; Hussein, M. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 2002, 120, 1268–1279. [Google Scholar] [CrossRef] [PubMed]
  44. Hepler, R.S.; Frank, I.R. Marihuana smoking and intraocular pressure. JAMA 1971, 217, 1392. [Google Scholar] [CrossRef] [PubMed]
  45. Allen, R.C.; Sheppard, J.D., III; Lattanzio, F., Jr.; Lichtman, A.; Crouch, E., Jr.; Williams, P. Ocular and systemic effects of WIN-55,212-2 in normotensive rabbits. Investig. Ophthalmol. Vis. Sci. 2003, 44, 4423. [Google Scholar]
  46. Hosseini, A.; Lattanzio, F.A.; Williams, P.B.; Tibbs, D.; Samudre, S.S.; Allen, R.C. Chronic topical administration of WIN-55,212-2 maintains a reduction in IOP in a rat glaucoma model without adverse effects. Exp. Eye Res. 2006, 82, 753–759. [Google Scholar] [CrossRef] [PubMed]
  47. Porcella, A.; Maxia, C.; Gessa, G.L.; Pani, L. The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur. J. Neurosci. 2001, 13, 409–412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Zhong, L.; Geng, L.; Njie, Y.; Feng, W.; Song, Z.-H. CB2 Cannabinoid Receptors in Trabecular Meshwork Cells Mediate JWH015-Induced Enhancement of Aqueous Humor Outflow Facility. Investig. Opthalmol. Vis. Sci. 2005, 46, 1988–1992. [Google Scholar] [CrossRef]
  49. Aymerich, M.S.; Aso, E.; Abellanas, M.A.; Tolon, R.M.; Ramos, J.A.; Ferrer, I.; Romero, J.; Fernández-Ruiz, J. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. Biochem. Pharmacol. 2018, 157, 67–84. [Google Scholar] [CrossRef] [Green Version]
  50. Yazulla, S. Endocannabinoids in the retina: From marijuana to neuroprotection. Prog. Retin. Eye Res. 2008, 27, 501–526. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  51. Pietrucha-Dutczak, M.; Amadio, M.; Govoni, S.; Lewin-Kowalik, J.; Smedowski, A. The role of endogenous neuroprotective mechanisms in the prevention of retinal ganglion cells degeneration. Front. Neurosci. 2018, 12, 1–23. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Tomida, I.; Pertwee, R.G.; Azuara-Blanco, A. Cannabinoids and glaucoma. Br. J. Ophthalmol. 2004, 88, 708–713. [Google Scholar] [CrossRef]
  53. Novack, G.D. Cannabinoids for treatment of glaucoma. Curr. Opin. Ophthalmol. 2016, 27, 146–150. [Google Scholar] [CrossRef]
  54. Panahi, Y.; Manayi, A.; Nikan, M.; Vazirian, M. The arguments for and against cannabinoids application in glaucomatous retinopathy. Biomed. Pharmacother. 2017, 86, 620–627. [Google Scholar] [CrossRef]
  55. Allingham, R.R. Shield’s Textbook of Glaucoma; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2011; pp. 390–399. [Google Scholar]
  56. Asproni, B.; Manca, I.; Pinna, G.; Cichero, E.; Fossa, P.; Murineddu, G.; Lazzari, P.; Loriga, G.; Pinna, G.A. Novel pyrrolocycloalkylpyrazole analogues as CB1 ligands. Chem. Biol. Drug Des. 2018, 91, 181–193. [Google Scholar] [CrossRef]
  57. Murineddu, G.; Ruiu, S.; Mussinu, J.-M.; Loriga, G.; Grella, G.E.; Carai, M.A.M.; Lazzari, P.; Pani, L.; Pinna, G.A. Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo(g)indazole-based ligands for cannabinoid receptors. Bioorg. Med. Chem. 2005, 13, 3309–3320. [Google Scholar] [CrossRef]
  58. Barth, F.; Congy, C.; Martinez, S.; Rinaldi, M. Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same. U.S. Patent US2005/192332A1, 1 September 2005. [Google Scholar]
  59. Lazzari, P.; Ruiu, S.; Pinna, G.A.; Murineddu, G. Pharmaceutical compounds. U.S. Patent US7485730B2, 3 February 2009. [Google Scholar]
  60. Mastinu, A.; Pira, M.; Pani, L.; Pinna, G.A.; Lazzari, P. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile. Behav. Brain Res. 2012, 234, 192–204. [Google Scholar] [CrossRef] [PubMed]
  61. Lazzari, P.; Distinto, R.; Manca, I.; Baillie, G.; Murineddu, G.; Pira, M.; Falzoi, M.; Sani, M.; Morales, P.; Ross, R.; et al. A critical review of both the synthesis approach and the receptor profile of the 8-chloro-1-(2′,4′-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo(6,7)cyclohepta(1,2-c)pyrazole-3-carboxamide and analogue derivatives. Eur. J. Med. Chem. 2016, 121, 194–208. [Google Scholar] [CrossRef]
  62. Stoit, A.R.; Lange, J.H.M.; Hartog, A.P.D.; Ronken, E.; Tipker, K.; van Stuivenberg, H.H.; Dijksman, J.A.R.; Wals, H.C.; Kruse, C.G. Design, Synthesis and Biological Activity of Rigid Cannabinoid CB1 Receptor Antagonists. Chem. Pharm. Bull. 2002, 50, 1109–1113. [Google Scholar] [CrossRef] [Green Version]
  63. Zhang, Y.; Burgess, J.P.; Brackeen, M.; Gilliam, A.; Mascarella, S.W.; Page, K.; Seltzman, H.H.; Thomas, B.F. Conformationally constrained analogues of N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716): Design, synthesis, computational analysis, and biological evaluations. J. Med. Chem. 2008, 51, 3526–3539. [Google Scholar] [CrossRef] [PubMed]
  64. Meye, F.J.; Trezza, V.; Vanderschuren, L.J.M.J.; Ramakers, G.M.J.; Adan, R.A.H. Neutral antagonism at the cannabinoid 1 receptor: A safer treatment for obesity. Mol. Psyc. 2013, 18, 1294–1301. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Lange, J.H.M.; Kruse, C.G.; Shadid, B. Compounds with a Combination of Cannabinoids-CB1 Antagonism and Acetylcholinesterase Inhibition. U.S. Patent US2008/0153867A1, 26 June 2008. [Google Scholar]
  66. Antel, J.; Gregory, P.-C.; Lange, J.H.M.; Firnges, M.; Reiche, D. Pharmaceutical Compositions Comprising CBX Cannabinoid Receptor Modulators and Potassium Channel Modulators. U.S. Patent US2007/0254862A1, 1 November 2007. [Google Scholar]
  67. Firnges, M.; Gregory, P.-C.; Antel, J.; Lange, J.H.M.; Waldeck, H. Pharmaceutical Compositions Comprising CB1 Cannabinoid Receptor Antagonists and Potassium Channel Openers for the Treatment of Obesity and Related Conditions. U.S. Patent US2006/0128673A1, 15 June 2006. [Google Scholar]
  68. Ralston, S.H.; Greig, I.R.; Ross, R.A.; Mohamed, A.I.I.; Van’t Hof, R.J. Cannabinoid Receptor Inverse Agonists and Neutral Antagonists as Therapeutic Agents for the Treatment Of Bone Disorders. WO2004/078261A1, 16 September 2004. [Google Scholar]
  69. Bellingham, M. Method and agents for reducing general anaesthetic induced neuroexcitation. WO2018/094470A1, 31 May 2018. [Google Scholar]
  70. Jones, D. End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat. Rev. Drug Discov. 2008, 7, 961–962. [Google Scholar] [CrossRef] [PubMed]
  71. Cinar, R.; Iyer, M.R.; Kunos, G. The therapeutic potential of second and third generation CB1R antagonists. Pharmacol. Ther. 2020, 208, 107477. [Google Scholar] [CrossRef]
  72. Nguyen, T.; Thomas, B.F.; Zhang, Y. Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development. Curr. Top. Med. Chem. 2019, 19, 1418–1435. [Google Scholar] [CrossRef]
  73. Murineddu, G.; Asproni, B.; Corona, P.; Piras, S.; Lazzari, P.; Ruiu, S.; Legnani, L.; Toma, L.; Pinna, G.A. Development of Oxygen-Bridged Pyrazole-Based Structures as Cannabinoid Receptor 1 Ligands. Molecules 2019, 24, 1656. [Google Scholar] [CrossRef] [Green Version]
  74. Lohray, B.B.; Lohray, V.B.; Srivastava, B. Novel Heterocyclic Compounds. WO2006/025069A2, 9 March 2006. [Google Scholar]
  75. Banerjee, K.; Jain, M.; Vallabh, A.; Srivastava, B.; Joharapurkar, A.; Patel, H. Synthesis and Biological Studies of a Novel CB1 Antagonist. Drug Res. 2015, 66, 33–40. [Google Scholar] [CrossRef] [PubMed]
  76. Mastinu, A.; Pira, M.; Pinna, G.A.; Pisu, C.; Casu, M.A.; Reali, R.; Marcello, S.; Murineddu, G.; Lazzari, P. NESS06M reduces body weight with an improved profile relative to SR141716A. Pharmacol. Res. 2013, 74, 94–108. [Google Scholar] [CrossRef]
  77. Lazzari, P.; Serra, V.; Marcello, S.; Pira, M.; Mastinu, A. Matabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats. Europ. Neuropsychopharmacol. 2017, 27, 667–678. [Google Scholar] [CrossRef] [PubMed]
  78. Fois, G.; Fattore, L.; Murineddu, G.; Salis, A.; Pintore, G.; Asproni, B.; Pinna, G.; Diana, M. The novel cannabinoid antagonist SM-11 reduces hedonic aspect of food intake through a dopamine-dependent mechanism. Pharmacol. Res. 2016, 113, 108–115. [Google Scholar] [CrossRef] [PubMed]
  79. Dore, A.; Asproni, B.; Scampuddu, A.; Gessi, S.; Murineddu, G.; Cichero, E.; Fossa, P.; Merighi, S.; Bencivenni, S.; Pinna, G.A. Synthesis, molecular modelling and SAR study of novel pyrazolo(5,1-f)(1,6)naphthyridines as CB2 receptor antagonists/inverse agonists. Bioorg. Med. Chem. 2016, 24, 5291–5301. [Google Scholar] [CrossRef] [PubMed]
Molecules 26 02126 g001 550
Figure 1. Chemical structure of representative cannabinoids.
Figure 1. Chemical structure of representative cannabinoids.
Molecules 26 02126 g001
Molecules 26 02126 g002 550
Figure 2. Design of cannabinoid CB1/CB2 receptor ligands.
Figure 2. Design of cannabinoid CB1/CB2 receptor ligands.
Molecules 26 02126 g002
Molecules 26 02126 sch001 550
Scheme 1. General synthetic route for the preparation of compounds I.
Scheme 1. General synthetic route for the preparation of compounds I.
Molecules 26 02126 sch001
Molecules 26 02126 g003 550
Figure 3. Structure of representative 1,4-dihydroindeno(1,2-c)pyrazoles (I). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [23]. Permission has been obtained and there is no copyright issue.
Figure 3. Structure of representative 1,4-dihydroindeno(1,2-c)pyrazoles (I). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [23]. Permission has been obtained and there is no copyright issue.
Molecules 26 02126 g003
Molecules 26 02126 g004 550
Figure 4. Structure of representative 1,4-dihydroindeno(1,2-c)pyrazoles (I) obtained by modification of carboxamide moiety of compound IAhX. Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [24].
Figure 4. Structure of representative 1,4-dihydroindeno(1,2-c)pyrazoles (I) obtained by modification of carboxamide moiety of compound IAhX. Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [24].
Molecules 26 02126 g004
Molecules 26 02126 g005 550
Figure 5. Structure of representative 1,4-dihydroindeno(1,2-c)pyrazoles (I) designed making use of molecular hybridization based on scaffold hopping. Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [26].
Figure 5. Structure of representative 1,4-dihydroindeno(1,2-c)pyrazoles (I) designed making use of molecular hybridization based on scaffold hopping. Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [26].
Molecules 26 02126 g005
Molecules 26 02126 g006 550
Figure 6. Structure and CB1/CB2 binding affinities of representative cyclopropyl-based 1,4-dihydroindeno(1,2-c)pyrazoles (I). Affinities at CB1 and CB2 receptors were evaluated by competition of (3H)-CP 55,940 in human CB1 or CB2 receptors transfected into HEK293 EBNA cells [29].
Figure 6. Structure and CB1/CB2 binding affinities of representative cyclopropyl-based 1,4-dihydroindeno(1,2-c)pyrazoles (I). Affinities at CB1 and CB2 receptors were evaluated by competition of (3H)-CP 55,940 in human CB1 or CB2 receptors transfected into HEK293 EBNA cells [29].
Molecules 26 02126 g006
Molecules 26 02126 g007 550
Figure 7. Structure of representative benzofuro(3,2-c)pyrazol-based derivatives (V). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [38].
Figure 7. Structure of representative benzofuro(3,2-c)pyrazol-based derivatives (V). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [38].
Molecules 26 02126 g007
Molecules 26 02126 g008 550
Figure 8. Structure of representative 1,4-dihydrothieno(2′,3′-4,5)cyclopenta(1,2-c)pyrazole-based derivatives (VII). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [40].
Figure 8. Structure of representative 1,4-dihydrothieno(2′,3′-4,5)cyclopenta(1,2-c)pyrazole-based derivatives (VII). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [40].
Molecules 26 02126 g008
Molecules 26 02126 g009 550
Figure 9. Structure of representative 1,4-dihydrothieno(3′,2′-4,5)cyclopenta(1,2-c)pyrazole-based derivatives (X). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [41].
Figure 9. Structure of representative 1,4-dihydrothieno(3′,2′-4,5)cyclopenta(1,2-c)pyrazole-based derivatives (X). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [41].
Molecules 26 02126 g009
Molecules 26 02126 g010 550
Figure 10. Structure of representative 1,4-dihydropyrazolo(3,4-a)pyrrolizine-based derivatives (XV). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse whole-brain membranes and in CHO cell membranes transfected with hCB2 receptors [56].
Figure 10. Structure of representative 1,4-dihydropyrazolo(3,4-a)pyrrolizine-based derivatives (XV). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse whole-brain membranes and in CHO cell membranes transfected with hCB2 receptors [56].
Molecules 26 02126 g010
Molecules 26 02126 g011 550
Figure 11. Structure of representative 4,5-dihydro-1H-benzo(g)indazole-based derivatives (II). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [57].
Figure 11. Structure of representative 4,5-dihydro-1H-benzo(g)indazole-based derivatives (II). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [57].
Molecules 26 02126 g011
Molecules 26 02126 g012 550
Figure 12. Structure of representative 4,5-dihydro-1H-thieno(2,3-g)indazole-based derivatives (VIII). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [59].
Figure 12. Structure of representative 4,5-dihydro-1H-thieno(2,3-g)indazole-based derivatives (VIII). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [59].
Molecules 26 02126 g012
Molecules 26 02126 g013 550
Figure 13. Structure of representative 4,5-dihydro-1H-pyrazolo(4,3-g)indolizine-based derivatives (XVI). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse whole-brain membranes and in CHO cell membranes transfected with hCB2 receptors [56].
Figure 13. Structure of representative 4,5-dihydro-1H-pyrazolo(4,3-g)indolizine-based derivatives (XVI). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse whole-brain membranes and in CHO cell membranes transfected with hCB2 receptors [56].
Molecules 26 02126 g013
Molecules 26 02126 g014 550
Figure 14. Structure of representative 1,4,5,6-tetrahydrobenzo(6,7)cyclohepta(1,2-c)pyrazole-based derivatives (III). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse whole-brain membranes and in CHO cell membranes transfected with hCB2 receptors [61].
Figure 14. Structure of representative 1,4,5,6-tetrahydrobenzo(6,7)cyclohepta(1,2-c)pyrazole-based derivatives (III). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse whole-brain membranes and in CHO cell membranes transfected with hCB2 receptors [61].
Molecules 26 02126 g014
Molecules 26 02126 g015 550
Figure 15. Structure of representative 4,5-dihydro-1H-benzo(2,3)oxepino(4,5-c)pyrazole-based derivatives (VI). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [73].
Figure 15. Structure of representative 4,5-dihydro-1H-benzo(2,3)oxepino(4,5-c)pyrazole-based derivatives (VI). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse cerebellum membranes and in mouse spleen homogenates, respectively [73].
Molecules 26 02126 g015
Molecules 26 02126 g016 550
Figure 16. Structure of representative 1,4,5,6-tetrahydropyrazolo(3,4-c)pyrrolo(1,2-a)azepine-based derivatives (XVII). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse whole-brain membranes and in CHO cell membranes transfected with hCB2 receptors [56].
Figure 16. Structure of representative 1,4,5,6-tetrahydropyrazolo(3,4-c)pyrrolo(1,2-a)azepine-based derivatives (XVII). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in mouse whole-brain membranes and in CHO cell membranes transfected with hCB2 receptors [56].
Molecules 26 02126 g016
Molecules 26 02126 g017 550
Figure 17. Structure of 4,5,6,7-tetrahydro-1H-benzo(7,8])cycloocta(1,2-c)pyrazole derivative IVAdX. Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in HEK-293 and CHO-K1 cell membranes, respectively [63].
Figure 17. Structure of 4,5,6,7-tetrahydro-1H-benzo(7,8])cycloocta(1,2-c)pyrazole derivative IVAdX. Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in HEK-293 and CHO-K1 cell membranes, respectively [63].
Molecules 26 02126 g017
Molecules 26 02126 g018 550
Figure 18. Structure of representative pyrazolo(5,1-f)(1,6)naphthyridine-based derivatives (5–7). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in transfected human CB1 and CB2 CHO cells [79].
Figure 18. Structure of representative pyrazolo(5,1-f)(1,6)naphthyridine-based derivatives (5–7). Affinities at CB1 and CB2 receptors were assessed by competition of (3H)-CP 55,940 in transfected human CB1 and CB2 CHO cells [79].
Molecules 26 02126 g018
Molecules 26 02126 sch002 550
Scheme 2. General synthetic route for the preparation of pyrazolo(5,1-f)(1,6)naphthyridine derivatives 5–7.
Scheme 2. General synthetic route for the preparation of pyrazolo(5,1-f)(1,6)naphthyridine derivatives 5–7.
Molecules 26 02126 sch002
Table
Table 1. Intraocular pressure (IOP) variation in old DBA/2J mice after administration of compounds XIhZ, XNhZ, XHhX and WIN-55,212-2 as reference compounds. The results are expressed as percent decrease of the IOP with respect to the animal basal IOP value [41].
Table 1. Intraocular pressure (IOP) variation in old DBA/2J mice after administration of compounds XIhZ, XNhZ, XHhX and WIN-55,212-2 as reference compounds. The results are expressed as percent decrease of the IOP with respect to the animal basal IOP value [41].
Intraocular Pressure Decrease (%)
Time of AdministrationCarrierXIhZXNhZXHhXWIN-55,212-2
(Minutes)20 µL40 µL50 µg100 µg50 µg100 µg50 µg100 µg50 µg100 µg
300.10.315.923.92.922.23.016.64.323.1
60−0.10.015.022.82.222.42.014.03.021.3
900.2−0.212.619.60.825.00.511.22.018.1
1200.00.011.721.71.516.711.721.71.913.2
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Asproni, B.; Murineddu, G.; Corona, P.; Pinna, G.A. Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB1/CB2 Receptor Interaction. Molecules 2021, 26, 2126. https://doi.org/10.3390/molecules26082126

AMA Style

Asproni B, Murineddu G, Corona P, Pinna GA. Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB1/CB2 Receptor Interaction. Molecules. 2021; 26(8):2126. https://doi.org/10.3390/molecules26082126

Chicago/Turabian Style

Asproni, Battistina, Gabriele Murineddu, Paola Corona, and Gérard A. Pinna. 2021. "Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB1/CB2 Receptor Interaction" Molecules 26, no. 8: 2126. https://doi.org/10.3390/molecules26082126

APA Style

Asproni, B., Murineddu, G., Corona, P., & Pinna, G. A. (2021). Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB1/CB2 Receptor Interaction. Molecules, 26(8), 2126. https://doi.org/10.3390/molecules26082126

Article Metrics

Back to TopTop